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Abstract
Low extracellular pH (pHe), that is characteristic of many tumours, tends to reduce the uptake of weakly basic drugs, such as
doxorubicin, thereby conferring a degree of physiological resistance to chemotherapy. It has been assumed, from pH-
partition theory, that the effect of intracellular pH (pHi) is symmetrically opposite, although this has not been tested
experimentally. Doxorubicin uptake into colon HCT116 cells was measured using the drug’s intrinsic fluorescence under
conditions that alter pHi and pHe or pHi alone. Acutely, doxorubicin influx across the cell-membrane correlates with the
trans-membrane pH-gradient (facilitated at alkaline pHe and acidic pHi). However, the protonated molecule is not
completely membrane-impermeant and, therefore, overall drug uptake is less pHe-sensitive than expected from pH-
partitioning. Once inside cells, doxorubicin associates with slowly-releasing nuclear binding sites. The occupancy of these
sites increases with pHi, such that steady-state drug uptake can be greater with alkaline cytoplasm, in contradiction to pH-
partition theory. Measurements of cell proliferation demonstrate that doxorubicin efficacy is enhanced at alkaline pHi and
that pH-partition theory is inadequate to account for this. The limitations in the predictive power of pH-partition theory
arise because it only accounts for the pHi/pHe-sensitivity of drug entry into cells but not the drug’s subsequent interactions
that, independently, show pHi-dependence. In summary, doxorubicin uptake into cells is favoured by high pHe and high
pHi. This modified formalism should be taken into account when designing manoeuvres aimed at increasing doxorubicin
efficacy.
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Introduction
The entry of weakly basic or weakly acidic molecules into cells
can show pH-dependence arising from differences in the
membrane permeability of their protonated and unprotonated
forms [1,2,3]. This so-called pH-partitioning is relevant to
chemotherapy because many anti-cancer drugs are protonatable
and tumours typically have substantially lower extracellular pH
(pHe) than normal tissue, whilst maintaining a modestly alkaline
intracellular pH (pHi) [3,4,5,6]. pH-partition theory has been
tested experimentally by correlating drug uptake or efficacy with
the trans-membrane pH gradient (DpH=pHe2pHi). Cellular
accumulation of the weakly-basic drug doxorubicin [7] has been
shown to decrease at low pHe, in accordance with pH-partition
theory [1,2,8,9]. The acidic extracellular milieu of tumours is
therefore predicted to confer a degree of physiological resistance to
weakly-basic drugs [9,10], and manoeuvres that raise pHe have
been proposed to improve doxorubicin efficacy [1,8]. Doxorubicin
resistance may also arise from sequestration of the drug into acidic
vesicles [11]. pH-partition theory has been applied to explain this
phenomenon, and manoeuvres that raise intra-vesicular pH (pHv)
have been shown to enhance doxorubicin efficacy [12,13].
Many studies of the pH-sensitivity of doxorubicin uptake, or its
cytotoxicity, have measured responses to changes in extracellular pH
[1,2,8,9]. Such manoeuvres will also change intracellular pH
because of the pHe-sensitivity of transporters that regulate the
cell’s acid-base balance [14]. The effect of pHi – independently of
pHe – on doxorubicin uptake has not been tested robustly. It
cannot, therefore, be excluded that higher drug uptake at alkaline
pHe arises from higher pHi, in an apparent contradiction to pH-
partition theory. Recent in vitro work has shown that doxorubicin
forms an adduct with DNA [15] in a pH-sensitive manner [16],
decreasing as pH is reduced below 7. This process may introduce
physiologically-relevant pHi-sensitivity of doxorubicin uptake into
cells, independently of pH-partitioning across the membrane.
Attempts have been made to disentangle the effects of pHi and
pHe on drug uptake by comparing cells with different pHe2pHi
relationships, for example, by comparing low-pH adapted CHO
cells with control cells [2]. Comparison between phenotypically-
distinct sub-populations can introduce additional variables that
may affect drug uptake. For instance, at pHe=7.4, when both
normal and low-pH adapted cells have similar pHi, doxorubicin
uptake was much higher in the former. Correlations between DpH
and drug uptake, deemed as evidence for the pH-partition theory,
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pHe,pHi), but not extended to symmetrically positive DpH. In
these studies, changes to pHi have typically been much smaller
than the associated changes to pHe, making it difficult to
characterise the importance of pHi in drug uptake. Similarly,
doxorubicin uptake into vesicles has been investigated in the
context of changing pHv at near-constant pHi [12,13]. Further
testing of pH-partition theory would require studies performed
under conditions where pHi is manipulated to a greater degree
than pHe or pHv.
In this study, we use doxorubicin’s intrinsic fluorescence to
study the drug’s uptake and accumulation over a range of pHi and
pHe values, manipulated by changing bathing medium pH (to
alter pHi and pHe in parallel), applying weak-acids at constant pHe
(to alter pHi) or inhibiting membrane-bound acid-base transport-
ers (to alter pHi at constant pHe). We then test the inferences made
from isolated cells on multi-cellular 3-D spheroids [17,18]. Finally,
the effects of changing pHi with pHe or pHi alone on doxorubicin
efficacy were tested using an index of proliferation. P53 wild-type
human colon HCT116 cells were used in the study, as these have
relatively low expression levels of the drug resistance-conferring P-
glycoprotein [19,20] and the proposed doxorubicin carrier
SLC22A16 [21]. In addition, these cells have well-characterised
pH regulation, little acid-extrusion by H
+ ATPase pumps (i.e. Na
+-
and HCO3
2-independent flux) and can form multi-cellular
spheroids [22]. Experimental data were analysed with a
mathematical model to dissect the relationships between pHi,
pHe and drug uptake.
Our results indicate that pH-partition theory alone is inade-
quate to fully account for the pH-sensitivity of doxorubicin uptake.
Firstly, we find that the protonated form of doxorubicin can cross
membranes, albeit slower than the unprotonated form. Secondly,
once inside the cell, the drug associates with nuclear binding sites
in a pH-dependent manner. We conclude that the behaviour of
free doxorubicin can be approximated by the pH-partition theory,
but its intracellular accumulation requires the introduction of a
pHi-sensitive drug-binding process. We propose that doxorubicin
accumulation is favoured by a combination of high pHe and high
pHi.
Methods
Solutions
All solutions were based on Hepes/Mes-buffered normal
Tyrode (125 mM NaCl, 4.5 mM KCl, 20 mM Hepes, 20 mM
Mes, 1 mM CaCl2, 1 mM MgCl2, pH adjusted to 7.4). To change
pHe (and, secondarily, pHi), solution pH was titrated to 6.4 or 6.8
or 7.8 (whilst maintaining osmolarity by adjusting NaCl). To
change pHi at constant pHe: (i) NaCl was iso-osmotically replaced
with 40 mM or 80 mM NaAcetate (reduces pHi), (ii) Na
+ was
replaced with N-methyl-D-glucamine (inactivates NHE and allows
CHE to acid-load cell), (iii) 5-(N,N-dimethyl) amiloride (DMA)
was added (inhibits NHE and allows CHE to acid-load cell), (iv)
Cl
2 was replaced with gluconate (inactivates CHE and allows
NHE to base-load cells), or (v) Hepes/Mes was replaced with
CO2/HCO3
2 (alters the steady-state pHe2pHi relationship by
activating additional pHi regulating transporters).
Imaging isolated cells under superfusion
Colon cancer HCT116 cells (provided by Cancer Research
UK; [17,23]) were grown in Dulbecco’s Modified Eagle’s Medium
(DMEM) containing NaHCO3, in an atmosphere of 5% CO2 for
48–72 hours until confluency. Prior to experiments, cells were re-
suspended in Hepes-buffered DMEM (for no more than 3 hours).
A 200 ml-aliquot of cell-suspension was applied to a poly-L-lysine
pre-treated coverslip, mounted at the base of a Perspex
superfusion chamber. After 10 minutes to allow for cell-adhesion
(and fluorescent dye-loading, where applicable), cells were
superfused with solution heated to 37uC at 2 ml/min [22]. By
switching between two solution lines, it was possible to change the
superfusate with a time-constant of ,8 sec. pHi was measured in
cells loaded with carboxy-SNARF-1 (excitation 514 nm, fluores-
cence emission collected at 580 nm and 640 nm). The emission
ratio was calibrated in units of pH by the ‘nigericin’ technique
[24]. In separate experiments, doxorubicin (50 mM) uptake was
measured using its intrinsic fluorescence (excitation 488 nm,
emission 580 nm). This signal was not significantly pH-sensitive
(Fig S1A), i.e. the protonated and unprotonated forms are equally
fluorescent. By confocally imaging an optical slice, it is possible to
measure fluorescence within cells and in the extracellular solution
simultaneously.
Measurements with flow cytometry
Cells were pre-equilibrated for 1 hour with a desired Hepes/
Mes-buffered solution to attain steady-state pHi. Cells were then
treated with doxorubicin (50 mM) for a further 2 hours. Drug
accumulation in cells was quantified with a Beckman Coulter
Quanta SC flow cytometer (excitation 488 nm; emission 580 nm)
in drug-free medium. Measurements were limited to 5 minutes
and back-extrapolated to account for slow release of doxorubicin
in drug-free bathing media. To measure pHi, cells were subjected
to the same procedure (with the exception of doxorubicin
treatment) and AM-loaded with carboxy-SNARF-1 for 10 minutes
before flow-cytometry (excitation 488 nm; emission 580 nm and
640 nm).
Culturing and imaging spheroids
HCT116 cells were cultured in McCoy’s 5A medium.
Aggregation into spheroids was initiated by plating 4610
6 cells
in 250 mL spinner flasks (Techne MCS, UK) spun at 40 rpm for
2–9 days. Spheroids were superfused with buffer containing
doxorubicin (50 mM) for 2 hours. To correct for the depth-
dependent decrease in light-emission, doxorubicin fluorescence
was imaged alternately with the pH-insensitive, UV-excitable and
spectrally-resolvable dye, 7-amino-4-methyl coumarin (AMC;
30 mM). Extracellular pH within the spheroid mass was measured
with fluorescein sulphonic acid (30 mM) [17].
Nuclear vs cytoplasmic doxorubicin fluorescence
HCT116 cells were grown as confluent monolayers and treated
with doxorubicin (50 mM) and the nuclear stain Hoechst 33342
(10 mg/ml) for 2 hours. Fluorescence from doxorubicin
(.580 nm) and from Hoechst (,480 nm) were excited at
488 nm and 405 nm, respectively. Doxorubicin fluorescence was
summed in nuclear regions (identified by Hoechst fluorescence)
and non-nuclear regions (with sub-threshold Hoechst fluores-
cence). See Figure S2 for details of the image-processing method.
Proliferation assay for determining doxorubicin efficacy
1.0610
5 cells were seeded per well in 96-well plates and
incubated for 48 hours. Confluent cells at the base of the wells
were washed with PBS twice and then bathed in Hepes/Mes-
buffered normal Tyrode solution at pH=7.4 (the control) or one
of five solutions that alter pHi: (i–ii) normal Tyrode titrated to
pH 6.4 or 7.8 to alter pHe and pHi, (iii–v) normal Tyrode at
pH 7.4 containing DMA or lacking Na
+ salts or Cl
2 salts to alter
pHi at constant pHe (NB: these manoeuvres change the balance of
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because the bulk extracellular volume is much larger than
intracellular volume). After allowing 45 minutes for cells to re-
equilibrate their trans-membrane pH gradient, solutions were
replaced with ones containing doxorubicin (1 to 300 mM). After
2 hours of drug treatment, cell proliferation was assessed using the
CellTiter Blue assay (Promega, UK). Proliferation was calculated
as the ratio of absorbance at 562 nm to 595 nm, normalized to
that ratio in the absence of doxorubicin (this will take into account
doxorubicin-independent differences in cell-survival in the six
bathing media used). At .550 nm, absorbance due to doxorubicin
is negligible.
Mathematical model of doxorubicin uptake
The model assumes that doxorubicin fluorescence is (i)
proportional to its concentration and (ii) a linear combination of
free and bound doxorubicin. The drug’s pK was taken as 8.2
[1,2,8,9]. Best-fitting was used to estimate the permeability
constant of the protonated and unprotonated forms (PHDox,P Dox),
the maximal binding capacity of the ‘receptor’ (Bmax) and its
association and dissociation constants (kon,k off). It was assumed
that both forms of drug bind equally to the ‘receptor’. The pH-
sensitivity of drug binding was modelled by scaling Bmax (i.e. non-
competitive; acid-dissociation constant KH) or by scaling kon (i.e.
competitive; acid-dissociation constant QH). The equations
describing the concentration of free doxorubicin ([DOX]) and
bound doxorubicin ([DOX*]) inside cells are:
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Results
Intracellular doxorubicin associates with a slowly-
releasing binding site
Colon HCT116 cells (resting pHi=7.2) were exposed tran-
siently to solution (pHe=7.4) containing 50 mM doxorubicin for 1,
2 and 5 minutes (Fig. 1A). This dose is adequately fluorescent,
potently cytotoxic over a broad pHe range [9] and can produce
significant binding to DNA for a more accurate characterisation of
drug accumulation in cells [16,25]. Doxorubicin wash-out was
considerably slower than its uptake. This asymmetry cannot be
explained in terms of the trans-membrane pH gradient (DpH of
only +0.2). The rise of cell-averaged fluorescence above the
extracellular background suggests that the drug concentrates inside
cells [11,13,15,26]. The experimental time-courses can be
simulated by accounting for doxorubicin-binding to an intracel-
lular ‘receptor’ (Fig. 1B) of fast association (kon) and slow
dissociation (koff) kinetics (Fig. 1C). Best-fitting values for the
receptor’s maximal binding capacity (Bmax), ‘on’ and ‘off’ rate
constants (kon and koff) were 506 mM, 32.5 s
216M
21 and
2.345610
24 s
21, respectively, giving a doxorubicin binding
constant of 7.2 mM. Total intracellular doxorubicin concentration
is therefore given by the sum of ‘free’ and ‘bound’ drug.
Low extracellular pH decreases the rate of doxorubicin
uptake and accumulation in isolated cells
HCT116 cells were exposed to doxorubicin at different
superfusate pH (Fig. 2A) to measure the drug’s initial uptake rate
and its steady-state accumulation as a function of the trans-
membrane pH gradient. Figure 2Ai illustrates the experimental
protocol and Figure 2Aii shows the pHi response to changes in
pHe. For measurements of the initial rate of drug uptake, it was
assumed that starting pHi is 7.2. Analyses of doxorubicin
accumulation at steady-state must, however, take into account
the slow, pHe-evoked changes in pHi.
In agreement with pH-partition theory, doxorubicin uptake was
slowest at acidic pHe (Fig. 2Aiii). The mathematical model was used
to best-fit these experimental data for the permeability constants of
the protonated and unprotonated forms of drug (PHDox;P Dox). If only
the unprotonated formof drug were able to enter cells, drug uptake at
pHe=6.4 should be ,9-fold lower than at pHe=7.4. Our data
suggest that doxorubicin uptake is less pHe-sensitive than this: uptake
at pHe=6.4(DpH=20.8) was only 1.7-fold lower than at pHe=7.4
(DpH=+0.2) (Fig. 3A). This would be expected if the protonated
drug could also permeate across cell-membranes. The pHe-sensitivity
of drug uptake can be simulated with a PDox of 0.041 s
21 and a 12-
fold lower PHDox. In summary, doxorubicin protonation does not
render it completely membrane-impermeant. Consequently, extra-
cellular acidification reduces the initial rate of drug uptake to a
smaller degree than predicted by pH-partition theory.
Intracellular doxorubicin accumulation was measured after 2.8,
3.3 and 7.5 hours and was found to attain a steady-state by
2.8 hours. Steady-state drug accumulation was lowest at acidic
pHe (Fig. 2Aiii). During the course of this experiment, the trans-
membrane pH gradient gradually decreases because pHi tends
towards pHe (Fig. 2Aii). According to pH-partition theory, the
time-courses of doxorubicin accumulation measured at different
pHe should gradually converge, having attained the greatest
separation initially, before the onset of the secondary pHi change.
The experimental data are contrary to this (see Fig. 3A vs 3B): the
initial rate of drug uptake was 1.7-fold lower at pHe=6.4
(DpH=20.8) than at pHe=7.4 (DpH=+0.2), but at steady-state,
drug accumulation was 2.0-fold lower at the more acidic pHe
(despite the narrowing of DpH to 20.2). The on-going
intracellular acidification at low pHe reduces doxorubicin accumu-
lation in cells (Fig. 2Aiii). While this is incompatible with pH-
partition theory, it could be explained by reduced doxorubicin
binding to ‘receptors’ at acidic pHi. These data fit best to a model
with pHi-dependence of binding capacity Bmax (i.e. non-compet-
itive model) rather than of affinity (i.e. competitive model). The
acid-dissociation constant (KH) that best describes the data was
estimated to be 10
27.44 (Fig. 2Aiv).
Low intracellular pH increases the rate of doxorubicin
uptake in isolated cells
pH-partition theory was tested further by comparing drug-
uptake at reduced pHi but unchanged pHe (Fig. 2Bi–ii). This was
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sodium acetate (to acid-load the cytoplasm) and 30 mM DMA (to
block acid-extrusion that would otherwise ensue). Acidification,
when confined to the intracellular compartment, increased the
initial rate of drug uptake, as expected from pH-partition theory
(Fig. 3C). However, after 11 min of exposure, drug accumulation
became larger at higher pHi values (Fig. 2Biii). An analogous
cross-over was observed with 40 mM sodium acetate at 14 min-
utes. This behaviour is not predicted by the pH-partition theory,
but could be explained by reduced drug-binding to the
intracellular ‘receptor’ at low pHi, as proposed herein. Model
simulations were again in good agreement with the data (Fig. 2Biii).
Intracellular pH is a principal determinant of doxorubicin
accumulation in its slowly-releasable form
The parameterised mathematical model was used to simulate
the steady-state concentration of ‘free’ and ‘bound’ doxorubicin as
a function of pHi and pHe (Fig. 3D, E, F) The trans-membrane
distribution of free doxorubicin is in agreement with pH-partition
theory, being greatest at low pHi and high pHe (Fig. 3E). The
concentration of bound doxorubicin increases with pHe (due to
increased influx of drug) and with pHi (due to increased binding of
drug). Overall, optimal doxorubicin uptake is attainable at high
pHi and pHe. This was tested further using flow cytometry [27].
The pHi of cells was manipulated by changing pHe or by
altering the balance between acid-loading and acid-extruding
membrane transporters, at constant pHe. In Hepes/Mes-buffered
(i.e. CO2/HCO3
2-free) media, resting pHi in HCT116 cells is set
by the balance of acid-extruding Na
+/H
+ exchange (NHE) and
acid-loading Cl
2/OH
2 exchange (CHE) [22]. By replacing
extracellular Na
+ isosmotically with N-methyl-D-glucamine or by
including the NHE inhibitor DMA (50 mM), CHE-flux drives pHi
to a more acidic level. Conversely, pHi can be driven in the
alkaline direction by NHE, when CHE is blocked by replacing
extracellular Cl
2 isosmotically with gluconate. After allowing
1 hour for the attainment of a new steady-state pHi, HCT116 cells
were treated with 50 mM doxorubicin for 2 hours. Figure 4Ai
shows doxorubicin fluorescence histograms for three individual
flow cytometric experiments. Parallel experiments were performed
in the absence of doxorubicin, on cells loaded with carboxy-
SNARF-1 to measure steady-state pHi. Figure 4Aii plots the
measured and simulated relationship between pHi and total
intracellular doxorubicin. In agreement with the mathematical
predictions, but in contradiction to pH-partition theory, doxoru-
bicin accumulation increases with pHi, and is further augmented
by raised pHe.
Doxorubicin, like other anthracyclines, targets DNA
[15,25,28,29]. The possibility that the nucleus hosts the pHi-
sensitive, slowly-releasing ‘receptor’ was tested by measuring
doxorubicin fluorescence in nuclear and extra-nuclear regions.
Nuclear regions were identified by using the DNA-binding stain,
Hoechst 33342 (Figure S2). HCT116 monolayers were equilibrat-
ed with solutions at pHe=7.4 (the control), pHe=6.4 (to reduce
pHi and pHe) and Na
+-free solution at pHe=7.4 (to reduce pHi at
constant pHe). Monolayers were then treated with doxorubicin
and Hoechst 33342 for two hours and then imaged confocally.
Doxorubicin was distributed near-uniformly in non-nuclear
regions, suggesting that the degree of sequestration into acidic
compartments is small in HCT116 cells. Nuclear sequestration of
doxorubicin, expressed as a ratio of total doxorubicin fluorescence
in nuclear to non-nuclear regions, was markedly reduced at low
pHi, irrespective of whether this was attained by reducing pHe or
removing extracellular Na
+ (Fig. 4B). In summary, the distribution
of doxorubicin between cytoplasm and the nucleus is pHi-sensitive.
Imaging uptake of doxorubicin in multi-cellular
spheroids
HCT116 cells were cultured as multi-cellular 3-D spheroids of
radius 170 to 450 mm. The extracellular spaces within the
spheroid-mass restrict the diffusion of metabolically-produced
acids. This establishes radial gradients of pHi and pHe, with the
lowest levels attained at the spheroid-core. Figure 5A shows the
relationship between spheroid radius and its core-pHe (measured
with fluorescein sulphonic acid). The extracellular space was
buffered by CO2/HCO3
2 or a mixture of Hepes+Mes, supplied
by the superfusate as 5% CO2/22 mM HCO3
2 or 20 mM
Hepes+20 mM Mes, respectively. These solutions provide a
similar level of mobile buffering capacity, resulting in comparable
pHe gradients (Fig. 5A). However, the presence of CO2/HCO3
2
buffer activates additional acid-base transporters (Na
+-HCO3
2 co-
transport and Cl
2/HCO3
2 exchange) which provide tighter pHi
control. This is illustrated by the relationship between pHe and
pHi measured in single cells under the two buffering regimes
(Fig. 5B). Replacement of Hepes/Mes buffer with CO2/HCO3
2
will raise pHi at the pHe levels recorded in spheroids [17,18]. pH-
Figure 1. Intracellular doxorubicin associates with a slowly-
releasing intracellular binding site. (A) HCT116 cells superfused
with Hepes/Mes buffer at pH=7.4, 37uC. Doxorubicin (DOX; 50 mM) was
applied transiently by switching rapidly between drug-free and drug-
containing solution (average of 25 cells, 6SEM). (B) Proposed model
with equilibria involving free and bound doxorubicin. (C) Mathematical
simulation showing the fast rise of intracellular doxorubicin upon
exposure, and its slow release upon reversal of the trans-membrane
concentration gradient.
doi:10.1371/journal.pone.0035949.g001
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uptake.
To measure doxorubicin uptake, spheroids were treated with
drug for 2 hours and then imaged for doxorubicin fluorescence.
Imaging alternately with 7-amino-4-methyl coumarin (AMC)
corrected for the depth-dependent loss of signal (Fig. 5C, D).
Drug uptake decreased with spheroid-depth, as expected from the
radially-decreasing pHe (Fig. 5E, F). In contradiction to pH-
partition theory, replacement of Hepes/Mes with CO2/HCO3
2
increased drug uptake for size-matched spheroids (Fig. 5E, F). This
observation is, however, consistent with the notion that alkaline
pHi facilitates doxorubicin accumulation onto nuclear binding
sites.
Figure 2. Effect of changing extracellular and intracellular pH on doxorubicin uptake. Time-courses show the average (6SEM) of at least
25 cells. (A) (i) Extracellular pH was changed by switching to superfusates titrated to pH 6.8 or 6.4, simultaneously with the application of 50 mM
doxorubicin. (ii) Intracellular pH measured in separate experiments using carboxy-SNARF-1. (iii) Intracellular doxorubicin, normalized to its
extracellular signal. Inset shows intracellular fluorescence at steady state, attained after 2.8 hours of drug-exposure. (iv) Simulated doxorubicin time-
courses. (B) (i) Intracellular pH was reduced to 6.7 at constant extracellular pH by superfusing cells with 80 mM acetate in the presence of the Na
+/H
+
exchange inhibitor, dimethyl amiloride (DMA; 30 mM). Doxorubicin was applied once pHi attained a steady-state. (ii) Intracellular pH measured with
carboxy-SNARF-1. (iii) Intracellular doxorubicin fluorescence, showing the cross-over of time-courses for pHi=7.2 and 6.7. (iv) Simulation of
doxorubicin-time-courses.
doi:10.1371/journal.pone.0035949.g002
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efficacy
Doxorubicin efficacy was quantified in terms of the dose
required to reduce cell proliferation by 50% (EC50). The effect of
intra- and extracellular pH on EC50 was determined in cells
equilibrated in solutions that alter pHi with pHe,o rp H i alone. For
control experiments, cells were incubated in normal Tyrode at
pH 7.4. To alter pHe and pHi, cells were incubated in normal
Tyrode titrated to pH 6.4 or 7.8. To alter pHi alone (pHe constant
at 7.4), cells were incubated in normal Tyrode containing 50 mM
DMA or in solutions lacking Na
+ or Cl
2 salts.
Figure 6A show the effect of changing pHi and pHe on the
doxorubicin dose-response curve. The efficacy of doxorubicin as a
cytotoxic drug increases (i.e. EC50 falls) as pHe and pHi are raised
in tandem. Under pH-partition theory, changes in pHi and pHe
should exert opposite effects on EC50. However, changes in pHe
evoke changes in pHi that are parallel but of smaller magnitude
(Fig. 5B). Consequently, the effects on EC50, shown in Figure 6A,
are likely to be dominated by the pHe-effect, and are consistent
with pH-partition theory (i.e. increasing pHe increases doxorubicin
membrane-permeability).
According to pH-partition theory, an increase in pHi (at
constant pHe) should decrease doxorubicin efficacy (i.e. raise EC50).
However, the experimental data shown in Figure 6B are contrary
to this and, instead, are supportive of the model proposed herein
featuring pHi-dependent binding of doxorubicin to its nuclear
target. Figure 6C plots EC50 values as a function of pHi attained
with the six experimental protocols, and shows that doxorubicin
efficacy increases (i.e. EC50 falls) as pHi is raised. This relationship
was steeper in experiments where pHi and pHe were changed in
parallel. This is because changes in pHi and pHe have synergistic
effects on doxorubicin uptake and its efficacy. In summary,
doxorubicin’s efficacy as a cytotoxic drug depends on pHi and pHe
in a manner predicted by the present model. These data also
illustrate the inadequacy of pH-partition theory in predicting the
effects of pHi on drug efficacy.
Discussion
Evaluation of pH-partition theory
pH-partitioning has been the principal theoretical framework
for describing the uptake of weakly acidic or basic drugs into cells.
Its predictions have been applied, with success, to explain
doxorubicin resistance in cancer cells. Doxorubicin efficacy has
Figure 3. Effect of intracellular and extracellular pH on drug uptake and accumulation. (A) Initial rate of doroxubicin uptake, measured at
constant intracellular pH, over a range of extracellular pH values (data from Fig. 2A) with best-fit. (B) Intracellular doxorubicin at steady-state,
normalized to extracellular concentration, over a range of extracellular pH values. Secondary axis plots steady-state pHi attained at given pHe. (C)
Initial rate of doxorubicin uptake, measured at constant extracellular pH, over a range of intracellular pH values (data from Fig. 2B) with best-fit. Model
predictions for the steady-state relationship between intracellular pH, extracellular pH and either (D) free, (E) bound or (F) total doxorubicin. Contour
labels denote total intracellular doxorubicin concentration, normalized to its extracellular concentration (50 mM).
doi:10.1371/journal.pone.0035949.g003
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investigations have suggested that the increase is less than
predicted from pH-partitioning alone [10]. Doxorubicin flux on
SLC22A16 [30] and MDR proteins [31] may produce discrep-
ancies from pH-partitioning, particularly if these fluxes are pH-
sensitive. However, the present work tested pH-partition theory on
colon HCT116 cells, a cell line with only modest SLC22A16 and
MDR1 expression [19,20,21].
Our experimental data are in partial agreement with pH-
partition theory. The initial rate of doxorubicin uptake (before
significant intracellular binding can occur) is favoured by a positive
trans-membrane pH gradient (pHe2pHi.0; Fig. 3D). However,
the measured uptake rates are less pHe-sensitive than expected
(Fig. 3A, C). We have inferred this to be evidence that the
protonated form of drug is not absolutely membrane-impermeant,
but instead can enter cells, albeit 12-fold slower than the
unprotonated drug. More substantial discrepancies between pH-
partitioning predictions and our data arise from drug-binding to
slowly-reversible (Fig. 1), pHi-sensitive (Fig. 2A) ‘receptors’ that are
most likely nuclear (Fig. 4B). Our estimated affinity constant for
doxorubicin (7.2 mM) is in the range determined previously for
DNA [28,29] and the estimated maximal binding capacity is
equivalent to 3610
8 base-pairs (every tenth base-pair of human
DNA). Our data cannot determine unequivocally if these binding
sites are selective for either protonated or unprotonated drug, but
the considerable difference between estimated receptor pKH (7.44)
and doxorubicin pK (8.2) argues against selectivity. Based on the
Figure 4. Importance of intracellular pH in determining
doxorobucin accumulation. (A) (i) Specimen histogram of intracel-
lular doxorubicin fluorescence (from .5000 cells) at different extracel-
lular pH. (ii) Plot of intracellular doxorubicin (6coefficient of variation)
versus intracellular pH. Black circles: intracellular pH manipulated by
varying extracellular pH. Grey symbols: intracellular pH manipulated at
constant extracellular pH. (B) Data from HCT116 monolayers treated
with doxorobicin and Hoechst 33342. Ratio of doxorubicin fluorescence
in nuclear (Hoechst 33342 positive) and non-nuclear regions quantifies
the degree of drug accumulation in the nucleus.
doi:10.1371/journal.pone.0035949.g004
Figure 5. Doxorubicin accumulation in multi-cellular spher-
oids. (A) Extracellular pH measured at the core of spheroids, as a
function of radius, under two buffering regimes: 20 mM Hepes/Mes and
5% CO2/22 mM HCO3
2. (B) Relationship between extracellular and
intracellular pH in single cells, under the two buffering regimes. (C)
Radial gradients of doxorubicin and 7-amino-4-methyl coumarin: the
ratio of these signals provides a measure of doxorubicin uptake
corrected for light-path and absorbance. (D) Ratiometric image showing
doxorubicin accumulation in a HCT116 spheroid, averaged in ten
concentric layers. (E) Doxorubic i na c c u m u l a t i o nd e c r e a s e sw i t h
spheroid depth, as expected from the depth-dependent decrease in
extracellular pH. Doxorubicin uptake is lower in Hepes/Mes-treated
spheroids, i.e. at lower intracellular pH. (F) Doxorubicin uptake at the
core of spheroids decreases with spheroid-size and is further reduced
by replacing CO2
/HCO3
2 buffer with Hepes/Mes.
doi:10.1371/journal.pone.0035949.g005
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support a non-competitive model of pH-sensitivity (i.e. H
+ ions
reducing receptor availability for drug-binding). Since nuclear pH
is in communication with cytoplasmic pH, drug-binding will
respond to changes in pHi rather than DpH. Importantly, the
analysis presented in Figure 3F suggests that drug accumulation is
similarly sensitive to changes in either pHi or pHe from
‘physiological’ levels of 7.2 and 7.4. The importance of pHi in
determining doxorubicin efficacy is illustrated experimentally in
the cell proliferation assay (Fig. 6). The evidence for increased
drug uptake and efficacy at alkaline pHi is contradictory to pH-
partitioning and emphasises the necessity of implementing our
novel model for describing the effect of pH on doxorubicin
resistance.
Limitations of using fluorescence as a measure of
concentration
The use of fluorescence intensity as a measure of doxorubicin
concentration may introduce errors due to dye self-quenching or
pH-sensitivity of excitation or emission spectra. These potential
artefacts are unlikely to affect the interpretation of our data.
Firstly, confocal imaging of cells at the base of a superfusion
chamber minimises self-quenching in the optical slice. Nonethe-
less, if doxorubicin fluorescence were to saturate at high drug-
concentrations, it would exacerbate the discrepancy between our
data (Fig. 2) and pH-partition theory, and support the herein
proposed model. Secondly, doxorubicin fluorescence is only
weakly pH-sensitive (Figure S1A). Fluorescence intensity may
change independently of concentration when doxorubicin dis-
solves into a medium of different dielectric constant, such as a non-
aqueous environment. The doxorubicin emission spectrum carries
a signature, quantified in terms of the 580 nm/640 nm fluores-
cence ratio, that correlates with the properties of the solvent [32].
Our measurements of this ratio under different bathing conditions
show no significant pH-related change in the drug’s environment
(Figure S1B). Collectively, these findings suggest that fluorescence
is a reasonable measure of doxorubicin concentration.
Conclusions
The efficacy of doxorubicin (and potentially other related drugs)
is pH-dependent because of (i) pH-partitioning across cell-surface
and vesicular membranes (which determines drug entry and its
organellar distribution) and (ii) the pH-sensitivity of binding to
nuclear sites (which sequesters doxorubicin in a slowly-releasable
form). Our study shows that changes to pHi exert opposite effects
on trans-membrane drug entry and on drug accumulation in
nuclear sites, but the latter emerges as dominant (per pH-unit) and
can determine overall efficacy, at least in HCT116 cells. These
influences should be considered carefully when addressing
resistance to chemotherapy. There have been three proposed
pH-interventions for increasing doxorubicin efficacy. The first is
alkalinisation of the extracellular space (e.g. titration to a higher
pHe or infusion of HCO3
2) which raises pHe and pHi [1,8]. The
second manoeuvre is to inhibit surface membrane-bound proteins
that acidify the extracellular space, such as extracellular-facing
carbonic anhydrases, Na
+/H
+ exchangers or Na
+-HCO3
2 co-
transporters [33,34] and thereby increase pHe. The third
intervention proposes to inhibit vesicular acidification, which
reduces drug sequestration into endosomes [12,13]. pH-partition
theory predicts that the second and third manoeuvres should
produce the more powerful effect on overcoming pH-related
chemo-resistance, because these raise pHe or pHv and decrease
pHi (i.e. tending to reverse the trans-membrane pH-gradient).
However, the present findings argue that the first manoeuvre will
have a more potent effect on improving doxorubicin uptake
because of the parallel rise in pHi and pHe. It is noteworthy that
inhibitors of acid-extruding proteins, proposed as anti-cancer
drugs [33], may decrease doxorubicin efficacy by reducing pHi,i f
the associated change in pHe is relatively small.
Supporting Information
Figure S1 Characterising doxorubicin fluorescence. (A)
Doxorubicin (50 mM) fluorescence was measured in Hepes/Mes
Figure 6. Doxorubicin efficacy as a function of intracellular pH.
Cell proliferation was measured using the CellTiter blue assay kit
(quantified as a ratio of absorbance at 562 nm and 595 nm).
Doxorubicin efficacy was determined from dose-response curves as
the concentration which results in a 50% decrease in proliferation
(EC50). EC50 was measured under six different conditions that change
pHi, with or without an associated change in pHe. (A) Determining EC50
under incubation with normal Tyrode solutions titrated to pH 7.4 (the
control), 6.4 or 7.8. Incubation under these conditions also changes pHi
(n=8 each). (B) Determining EC50 under incubation with solutions at
pHe=7.4 containing 50 mM DMA or lacking Na
+ salts or Cl
2 salts (n=8
each). These manoeuvres change pHi by altering the balance of acid/
base fluxes across membranes (but do not alter pHe significantly
because of the dilution effect into the large extracellular volume). (C)
EC50 plotted against pHi (see Fig. 4Aii). Alkaline pHi increases
doxorubicin efficacy (decreases EC50).
doi:10.1371/journal.pone.0035949.g006
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fluorescence emission is only mildly pH-sensitivity (,5% per pH
unit). (B) Intracellular doxorubicin fluorescence ratio measured
flow cytometrically at 580 nm and 640 nm. This ratio carries a
signature that describes changes to the ambient environment of
doxorubicin. The constancy of the ratio suggests that the drug
remains in an aqueous environment.
(TIF)
Figure S2 Measuring the nuclear versus non-nuclear
doxorubicin accumulation. HCT116 monolayers were grown
to confluency and then incubated in buffer solution (of desired pH
and salt composition). Monolayers were then loaded with Hoechst
33342 and doxorubicin. (A) Doxorubicin fluorescence (488 nm
excitation) recorded confocally, showing signal in nuclear and non-
nuclear regions. (B) Hoechst 33342 fluorescence (405 nm
excitation) used to identify nuclei. (C) Doxorubicin fluorescence
in nuclear regions identified on the basis of supra-threshold
Hoechst 33342 signal. The ratio of doxorubicin fluorescence in
nuclear and non-nuclear regions was determined as (nuclear
doxorubicin fluorescence) divided by (total doxorubicin fluores-
cence minus nuclear doxorubicin fluorescence).
(TIF)
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